Abstract: A rinse off hair conditioning composition comprising: (a) about 0.05 to about 5% by weight of cationic surfactant, (b) 0.01 to 10% by weight of an emulsion polymerised dimethiconol nonionic conditioning polymer having the formula: HO—Si(CH3)2—O—[Si(CH3)2—O—]nSi(CH3)2—OH where n is greater than 2700, and (c) water. The invention also comprises a method of making a conditioning composition.

Abstract: A solid concentrated agrochemical composition comprising a homogeneous mixture of: (1) one (or a number of) concentrated compositions A in the form of dispersible granules, each granule containing at least one active material and not containing an effervescent agent, and having a cumulative pore volume of between 0.17 and 0.35 ml/g and having an apparent density of between 0.35 and 0.8 g/cm3; and (2) a concentrated composition B in the form of dispersible granules, each granule containing an effervescent agent and not containing an active material, and having a cumulative pore volume of between 0.020 and 0.13 ml/g and having an apparent density of between 0.8 and 1.5 g/cm3; the A/B quantitative ratio being between 0.01 and 30. A containerization system comprising said agrochemical composition within a bag whose wall is a film consisting of a film-forming material which is soluble or dispersible in water.

Abstract: A method of treating diseases caused by sebaceous gland disorders, in humans and animals, which comprises administering to said humans and animals a composition comprising a sebaceous gland secretion inhibiting amount of an active compound comprising an acyl coA cholesterol acyl transferase (ACAT) inhibitor or prodrug therefor. A composition for use in treating diseases caused by sebaceous gland disorders such as acne in humans and animals which comprises a sebaceous gland secretion inhibiting amount of an acyl coA cholesterol acyl tanferase (ACAT) inhibitor or prodrug therefor and, optionally, a pharmaceutically acceptable carrier.

Abstract: A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.

Abstract: The invention relates to new liquid and readily pumpable o/w emulsifiers containing a1) alkyl and/or alkenyl oligoglycosides, a2) fatty acid N-alkyl polyhydroxyalkylamides and/or a3) acyl glutamates and b) polyol polyhydroxystearates, with the proviso that the ratio by weight of a) to b) is in the range from 90:10 to 10:90.

Abstract: A cream formulation for topical application to an external portion of a human body. A one ounce preparation of such cream formulation includes active ingredients consisting essentially of a predetermined weight of an aloe vera gel compound present in the topical formulation generally in a weight range of between about 3 grams and about 10 grams. A predetermined weight of a preselected zinc compound present in the topical formulation generally in a weight range of between about 0.4 grams and about 1.5 grams. A predetermined weight, expressed as IU, of vitamin E present in the topical formulation generally in a weight range of between about 200 IU and about 9000 IU. The balance of such one ounce preparation of the topical formulation being made up of water, organic solvents, carriers and emollients.

Abstract: A chitosan-based polymeric nitric oxide donor composition comprising a modified chitosan polymer and a nitric oxide [N2O2] dimer, wherein the nitric oxide [N2O2] dimer is bonded directly to the backbone of the modified chitosan polymer without further binding through a nucleophile residue or moiety. The chitosan-based polymeric nitric oxide donor composition is capable of site specific delivery and controlled release of nitric oxide under physiological conditions. The chitosan-based polymeric nitric oxide donor composition further provides a carrier having medically beneficial properties. A method is further included for preparing a chitosan-based polymeric nitric oxide donor composition comprising reacting a nitric oxide dimer (80-100 p.s.i.) with a modified chitosan polymer in the presence of sodium methoxide at room temperature.

Abstract: Sustained release formulations for topical ophthalmic administration are disclosed. The formulations comprise a basic active, a polyanionic polymer and a poly(styrenedivinyl) benzene cation exchange resin having a degree of cross-linking from about 4 to about 4.5%.

Abstract: A method of forming a diffusion barrier on an article of a polymer blend of (i) a high surface energy polymer and (ii) a low surface energy polymer. Most commonly the low surface energy polymer is an organosilicon polymer, as a polysilane or a polysiloxane. The surface of the article is exposed to ozone and ultraviolet radiation to form a diffusion barrier.

Abstract: Foamable dental fluoride compositions containing a water-soluble fluoride component in an amount sufficient to provide from about 0.5 to about 10% by weight available fluoride are disclosed. The compositions include an oil in water emulsion which is preferably dispensed in combination with an aerosol propellant to provide microcell-stable foam which exhibits enhanced foam retention properties. Methods of treating teeth with fluoride and methods of preparing the foam are also disclosed.

Abstract: The present invention describes a crosslinked aliphatic polyoxaamide polymer and blends thereof that may be used to produce hydrogels, surgical devices such as catheters, molded devices, and the like. The crosslinked aliphatic polyoxaamide of the present invention are formed by crosslinking an aliphatic polyoxaamide having a first divalent repeating unit of formula I: [X—C(O)—C(R1)(R2)—O—(R3)—O—C(R1)(R2)—C(O)—]  I and a second repeating unit selected from the group of formulas consisting of: [—Y—R17—]T,  II [—O—R5—C(O)—]B,  III and ([—O—R9—C(O)]P—O—)LG  XI and combinations thereof, wherein X and Y are selected from the group consisting of —O— and —N(R)—, provided both X and Y are not both —O— and may be blended with a second polymer that is preferably biocompatable.

Abstract: Method for enhancing the immune system of a patient by orally administering to the patient safflower seeds or an extract of safflower seeds in combination with a pharmaceutically acceptable vehicle.

Abstract: Sustained release oral solid dosage forms comprising agglomerated particles of a therapeutically active medicament in amorphous form, a gelling agent, an ionizable gel strength enhancing agent and an inert diluent, as well as processes for preparing and using the same are disclosed. The sustained release oral solid dosage forms are useful in the treatment of hypertension in human patients.

Abstract: The present invention relates to methods in which ion exchange resins are used to reduce the amount of substances which interfere with nucleic acid hybridization in samples. The methods also stabilize the samples. Kits containing the ion exchange resins render the methods convenient to use.

Abstract: Disclosed is a method of producing a polyphenol-containing composition derived from grapes, the method including: preparing a liquid grape extract which includes polyphenols; contacting the liquid extract with a separation medium which fractionates the components of the extract; and recovering that fraction in which the polyphenols are present. Also disclosed is a method of enriching the composition with added flavonol.

Abstract: A delayed and sustained release composition of an additive and/or toxic agent such as nicotine is delivered systemically in therapeutic amounts while avoiding the peak plasma levels which gives rise to addiction and/or toxic side effects. The composition is delivered for absorption predominantly from the colon.

Abstract: The present invention relates to topical products intended for use as prophylactic or curative agents for bacterial skin infections, containing at least one polymeric complex substantially consisting of hydrogen peroxide, a suitable polymer for the complex formation thereof, possibly another bactericidal compound and possibly a metal salt or a metal colloid.

Abstract: This invention relates to a method of treating vascular proliferative responses in a patient that comprises intravenously administering to the patient a proliferative response inhibiting amount of poly(arginine).

Abstract: An improved diluent for the preparation of cisplatin suspensions from a lyophilized powder is provided. The diluent contains a pharmaceutically acceptable nonionic surfactant, which improves the accuracy and homogeneity of the therapeutic formulation. The suspension may be used directly, or may be used in preparing gel formulations for direct injection into a neoplastic lesion or surrounding tissue.

Abstract: Disclosed are compositions of nonionic siloxane alkoxylates with aminopolyalkyleneoxide surfactants which are useful in treating plants, for instance as adjuvants for pesticides including in particular herbicides. These compositions overcome the antagonism associated with nonionic trisiloxane alkoxylates on pesticide uptake in plants.